Jun. 17 at 12:50 PM
📈 PM Update – 9:00am EST
$ACXP – Acurx published Phase 2b results for ibezapolstat in The Lancet Microbe, hitting key endpoints for C. diff infection. Strong data backs further development.
$FGL – Founder Group signed an MoU with GCL System Integration to collaborate on solar module production and supply chain growth.
$DATS – DatChat’s RPM Interactive filed an S-1, signaling plans for potential capital raise and expansion.
$CERO – CE-Ro Therapeutics received FDA Orphan Drug Designation for its cancer drug candidate—boosts potential incentives and regulatory support.
$PRPH – ProPhase Labs reported strong clinical data for its Equivir supplement, showing effective antiviral activity in respiratory infection models.
⚡ Market Tone: Biotech and energy names lead the morning with filings, trial results, and deal announcements—setting the tone for a catalyst-heavy session.
